Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
Provided By PR Newswire
Last update: Nov 7, 2024
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -
- IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) -
Read more at prnewswire.comNASDAQ:TYRA (9/17/2025, 1:41:14 PM)
12.38
+0.02 (+0.16%)
Find more stocks in the Stock Screener
